Perrigo (PRGO) Change in Accured Expenses (2013 - 2026)
Perrigo (PRGO) reported Change in Accured Expenses of -$24.9 million for Q1 2026, down 35.33% year-over-year from -$38.5 million in Q1 2025, and down 32.45% quarter-over-quarter from -$18.8 million in Q4 2025.
Perrigo (PRGO) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Change in Accured Expenses data on file, last reported at -$24.9 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$24.9 million, down 35.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$23.0 million (down 172.1% YoY), and the FY2025 annual result was -$16.5 million, down 1169.23% from the prior year.
- Change in Accured Expenses fell to -$24.9 million in Q1 2026 per PRGO's latest filing, from -$18.8 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $72.6 million in Q4 2024 and troughed at -$66.0 million in Q4 2023.
- A 5-year average of -$7.9 million and a median of -$8.2 million in 2023 frame the typical range for Change in Accured Expenses.
- On a YoY basis, Change in Accured Expenses climbed as much as 3376.47% in 2023 and fell as far as 2969.57% in 2023.
- A 5-year view of Change in Accured Expenses shows it stood at $2.3 million in 2022, then tumbled by 2969.57% to -$66.0 million in 2023, then surged by 210.0% to $72.6 million in 2024, then slumped by 125.9% to -$18.8 million in 2025, then plunged by 32.45% to -$24.9 million in 2026.
- Business Quant data shows PRGO's Change in Accured Expenses at -$24.9 million in Q1 2026, -$18.8 million in Q4 2025, and $25.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn | -24.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -24.90 Mn |
| Mar 28, 2026 | -24.90 Mn |
| Dec 31, 2025 | -18.80 Mn |
| Dec 31, 2025 | -18.80 Mn |
| Sep 27, 2025 | 25.90 Mn |
| Sep 27, 2025 | 25.90 Mn |
| Jun 28, 2025 | -5.20 Mn |
| Jun 28, 2025 | -5.20 Mn |
| Mar 29, 2025 | -18.40 Mn |
| Mar 29, 2025 | -18.40 Mn |
| Dec 31, 2024 | 72.60 Mn |
| Dec 31, 2024 | 72.60 Mn |
| Sep 28, 2024 | -57.00 Mn |
| Sep 28, 2024 | -57.00 Mn |
| Jun 29, 2024 | 34.70 Mn |
| Jun 29, 2024 | 34.70 Mn |
| Mar 30, 2024 | -51.60 Mn |
| Mar 30, 2024 | -51.60 Mn |
| Dec 31, 2023 | -66.00 Mn |
| Dec 31, 2023 | -66.00 Mn |